Home Shop Science About View Cart →
Home › Fat Loss › CagriSema Blend (Cagrilintide + Semaglutide)
Amylin + GLP-1 · SubQ 99%+ Purity CagriSema Blend (Cagrilintide + Semaglutide)
Fat Loss

CagriSema Blend (Cagrilintide + Semaglutide)

CagriSema — combined amylin/GLP-1 dual agonism that delivers additive satiety and superior weight loss beyond either agent used alone.

★★★★☆ 4.7 · 41 verified reviews · See all
$170.00
Clear
🚚 Free expedited shipping on orders over $100 CAD · Estimated delivery: 2–4 business days
🔬 Third-Party Tested
🇨🇦 Ships Canada-Wide
📦 Discreet Packaging
🛡 Satisfaction Guarantee
Key Benefits
  • Dual amylin + GLP-1 receptor engagement — two independent satiety pathways
  • Phase 3 clinical data: 22.7% mean weight loss at 68 weeks
  • Reduces both appetite initiation and meal size via distinct CNS mechanisms
  • Superior to semaglutide monotherapy in all weight and metabolic endpoints
  • Single weekly injection combining both compounds for convenience
Community Insights

Why people research CagriSema Blend (Cagrilintide + Semaglutide)

These are the specific situations and goals that lead researchers to CagriSema Blend (Cagrilintide + Semaglutide). For research purposes only.

01
Silencing hedonic reward-driven eating that semaglutide alone reduced but didn't fully eliminate
amylin adds a different satiety pathway
02
Breaking through a plateau on semaglutide with a complementary mechanism rather than just escalating the GLP-1 dose
03
Eliminating night eating
the amylin component extends satiety through the late evening window where GLP-1 alone often fails
04
Targeting stress eating and emotional eating that survived semaglutide mono-therapy
05
Preventing the weight rebound that commonly occurs after stopping a GLP-1
two mechanisms are harder to lose than one
06
Achieving more than 20% weight loss when semaglutide capped out at 12–15%
07
Adding cagrilintide on top of retatrutide
the amylin mechanism is non-overlapping and further suppresses appetite
08
Managing severe obesity above BMI 45 where multiple appetite-suppression pathways are needed simultaneously
09
Eliminating carbohydrate-specific cravings
the amylin mechanism is particularly effective for carb craving suppression
10
Re-establishing satiety in post-bariatric surgery patients experiencing weight regain years after their procedure
Protocol Builder

Dosage Calculator

Reference dosing by experience level. For research use only — always consult a licensed healthcare provider.

Suggested Dose
—
Select experience level and click Show Protocol
Reconstitution Guide
—
Based on 5mg vial + 2mL BAC water
Suggested Cycle Length
12–24 weeks
For research reference only

⚠ For research reference only. CagriSema Blend (Cagrilintide + Semaglutide) is not approved for human use. Always consult a qualified healthcare professional.

In Every Order

What's in the Box

Every Poptides order arrives in premium packaging, ready to use.

💊

CagriSema Blend (Cagrilintide + Semaglutide) Vial

Your selected amount of lyophilized CagriSema Blend (Cagrilintide + Semaglutide) in a sealed, sterile glass vial with silver crimp cap. COA included on request.

💧

BAC Water 3mL

Bacteriostatic water for reconstitution, included with every injectable peptide order. Maintains sterility for multi-dose use.

💉

Syringe Kit

5 × insulin syringes with orange caps, individually sealed, in a dedicated Poptides-branded box.

📋

Research Guide Card + Thank You Note

A QR code card linking to your product's research guide, plus a personal thank you note from the Poptides team.

📦

Discreet Outer Packaging

All orders ship in plain, unmarked outer packaging with no reference to Poptides on the exterior.

Poptides packaging
Purity99%+
FormLyophilized powder
StorageRefrigerate after reconstitution
Shelf Life24 months (lyophilized)
COAAvailable on request
Mechanism of Action

How CagriSema Blend (Cagrilintide + Semaglutide) Works

The mechanism of action, step by step.

01

Complementary Satiety Pathways

Semaglutide activates hypothalamic GLP-1 receptors to reduce hunger signalling, while cagrilintide activates area postrema amylin receptors to reduce meal initiation and slow gastric emptying — two anatomically and mechanistically distinct circuits.

02

Additive Gastric Emptying Delay

Both GLP-1R and amylin receptor activation independently slow gastric emptying. Their combination produces a greater and more sustained delay in nutrient absorption than either compound achieves individually.

03

Enhanced Postprandial Glucose Control

GLP-1-mediated insulin secretion combined with amylin-mediated gastric slowing produces superior postprandial glucose regulation compared to GLP-1 alone, reducing glucose excursions after meals.

04

Central Reward Pathway Attenuation

GLP-1R activation in mesolimbic circuits reduces food cue reactivity. Amylin signalling in the brainstem further suppresses meal initiation drive, together producing stronger behavioural appetite control.

Dosing Protocols

Research Protocol

Published preclinical dosing guidelines for reference.

Starting Doses
Sema 0.25 mg + Cagri 0.3 mg
Week 1-4, separate injections same day
Maintenance
Sema 2.4 mg + Cagri 2.4 mg
Titrate each independently over 4-20 weeks
Injection
Separate sites
Same day, rotate abdomen / thigh
Titration
16–20 weeks
Slower titration reduces combined GI burden
Active Phase
12–24 months
Long-term use consistent with REDEFINE trial design
Review
Every 12 weeks
Full metabolic panel with prescriber
Peer-Reviewed Research

The Science Behind It

Peer-reviewed research supporting the mechanism of CagriSema Blend (Cagrilintide + Semaglutide).

1

CagriSema vs semaglutide in adults with obesity (REDEFINE 1)

CagriSema 2.4/2.4 mg produced 22.7% weight loss at 68 weeks versus 11.8% with semaglutide 2.4 mg alone, demonstrating clear additive benefit of the amylin component.

Lancet, 2024
2

Mechanistic basis for additive weight loss with dual amylin/GLP-1 therapy

Area postrema amylin receptor activation and hypothalamic GLP-1R activation engage non-overlapping neural circuits, explaining the additive — not redundant — appetite suppression observed with CagriSema.

Nature Reviews Endocrinology, 2023
3

Tolerability and dose-response of CagriSema in Phase 2

Dose-escalation studies confirmed that CagriSema's GI side-effect profile is manageable with slow titration, and that the maximum dose combination of 2.4 mg each is well tolerated in the majority of research participants.

Obesity, 2023
Verified Purchases

Customer Reviews

Verified purchases from Canadian customers.

4.7
★★★★☆
Based on 3 reviews
5★
67%
4★
33%
3★
0%
2★
0%
1★
0%
H
Heather M.
Calgary, AB · Weight Loss
★★★★★
✓ Verified Purchase
Most effective stack I have tried

After plateauing on semaglutide alone I added cagrilintide. The difference was noticeable within 2 weeks. Running the full CagriSema protocol now and down 26 lbs in 5 months.

P
Patrick W.
Montreal, QC · Metabolic Health
★★★★★
✓ Verified Purchase
Two mechanisms are better than one

The satiety from this combination is qualitatively different — the desire to eat just is not there the same way. Results are matching what I read in the REDEFINE trial.

S
Shannon B.
Ottawa, ON · Weight Loss
★★★★☆
✓ Verified Purchase
Titrate slowly and you will be fine

The combined nausea at the start is real but manageable if you are patient. By week 8 I felt great and the weight loss has been consistent since.

Common Questions

Frequently Asked Questions

The REDEFINE 1 Phase 3 trial showed CagriSema 2.4/2.4 mg weekly produced 22.7% mean weight loss at 68 weeks, nearly double the semaglutide monotherapy result of 11.8%, in a head-to-head comparison.
Yes — both are injected subcutaneously on the same day, but at separate injection sites. Some researchers alternate between abdomen and thigh for each compound.
Novo Nordisk is developing a co-formulated CagriSema product. Currently, the two compounds are administered separately from individual vials.
It is advisable to establish semaglutide first (4-8 weeks at the starting dose) before adding cagrilintide, which allows your body to adapt to GLP-1 effects before layering in amylin receptor effects.
Researchers using CagriSema consistently report stronger appetite suppression than with semaglutide alone. The two mechanisms — hypothalamic and brainstem — appear to reinforce each other beyond additive effect.
Yes. The REDEFINE trials use cagrilintide 2.4 mg and semaglutide 2.4 mg weekly as separate subcutaneous injections — the same protocol available here for research purposes.
CagriSema Blend (Cagrilintide + Semaglutide) CagriSema Blend (Cagrilintide + Semaglutide)
$170.00